TherapeuticsMD (TXMD) Misses Q3 EPS by 9c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/3/2026
- Wall St ends higher as stocks reclaim some shine
- Broadcom raises AI chip forecast as Big Tech keeps writing bigger checks
- Snowflake soars 20% on earnings beat and raised guidance
- Oil settles 1% higher, as US-Iran strikes threaten supplies
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
TherapeuticsMD Announces Third Quarter 2024 Financial Results
November 12, 2024 4:05 PM ESTBOCA RATON, Fla.--(BUSINESS WIRE)-- TherapeuticsMD, Inc. (TherapeuticsMD or the Company) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the third quarter ended September 30, 2024.
Third Quarter 2024 Financial Results
Net Income (Loss) from Continuing Operations
Net loss from continuing operations was $(567) thousand, or $(0.05) per basic and diluted common share, compared to a net loss of $(1.4) million, or $(0.13) per basic and diluted common share, for the third quarter of 2023.License and Service Revenues from Continuing... More
